title: Factors for hepatitis B vaccination and abnormal liver function in Chinese patients with inflammatory bowel disease: a single center experience.
abstract: OBJECTIVE
  We aimed to determine the prevalence of chronic and past hepatitis B virus (HBV) infection in Chinese patients with inflammatory bowel disease (IBD), and to determine the risk factors associated with having received no vaccination for HBV and abnormal liver function among our patients.
  
  
  METHODS
  The prevalence of chronic or past infection with HBV infection and effective HBV vaccination were determined in patients with IBD who attended the IBD Clinic of the Queen Mary Hospital in Hong Kong, China. Risk factors associated with the absence of HBV vaccination and abnormal liver function were identified.
  
  
  RESULTS
  A total of 267 Chinese IBD patients (166 ulcerative colitis and 101 Crohn's disease) were enrolled. The mean follow-up period was 10.5 years. Chronic and past HBV infection was detected in 6.7% and 28.5% patients, respectively. Altogether 102 patients lacked effective HBV vaccination. Multivariate analysis found that elder age at diagnosis of IBD (OR 1.02, 95% CI 1.00-0.94) and the absence of using thiopurine (OR 0.53, 95% CI 0.29-0.94) were associated with the presence of anti-HBs. Abnormal liver function was detected in 27 (10.1%) patients. The use of anti-tumor necrosis factor agents (OR 4.6, 95% CI 1.3-16.0), previous bowel resection (OR 3.7, 95% CI 1.5-9.2) and male gender (OR 4.4, 95% CI 1.4-13.7) were significant risk factors for abnormal liver function.
  
  
  CONCLUSIONS
  The use of thiopurine and younger age at diagnosis were associated with no vaccination against HBV in Chinese IBD patients. Chronic or past HBV infection was, however, not associated with abnormal liver function in these patients.
authors.affiliation: Department of Medicine, University of Hong Kong, Queen Mary Hospital, Hong Kong, China.
authors.forename: Wai K
authors.initials: WK
authors.lastname: Leung
authors.forename: Kevin Sh
authors.initials: KSh
authors.lastname: Liu
authors.forename: Wai-Kay Walter
authors.initials: WK
authors.lastname: Seto
authors.forename: Kwok-Hung
authors.initials: KH
authors.lastname: Chan
authors.forename: Teresa
authors.initials: T
authors.lastname: Tong
authors.forename: Man-Fung
authors.initials: MF
authors.lastname: Yuen
authors.forename: Ching-Lung
authors.initials: CL
authors.lastname: Lai
authors.forename: Ivan Fn
authors.initials: IF
authors.lastname: Hung
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D000410:Alanine Transaminase / Q000097:blood; D005260:Female; D005500:Follow-Up Studies; D006510:Hepatitis B Antibodies / Q000097:blood; D006514:Hepatitis B Surface Antigens / Q000097:blood; D017325:Hepatitis B Vaccines / Q000008:administration & dosage*; D019694:Hepatitis B, Chronic / Q000150:complications* / Q000503:physiopathology / Q000517:prevention & control; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D015212:Inflammatory Bowel Diseases / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology; D008099:Liver / Q000503:physiopathology*; D008297:Male; D015122:Mercaptopurine / Q000031:analogs & derivatives / Q000627:therapeutic use; D008875:Middle Aged; D012307:Risk Factors; D014611:Vaccination / Q000706:statistics & numerical data
chemical_list: D006510:Hepatitis B Antibodies; D006514:Hepatitis B Surface Antigens; D017325:Hepatitis B Vaccines; D007166:Immunosuppressive Agents; C488629:azathiopurine; D015122:Mercaptopurine; D000410:Alanine Transaminase
keywords: Chinese; hepatitis B; thiopurine; vaccine